In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Additional individuals might be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "increase-on" therapy. In Segment C, https://abbv-744brd4inhibitorcanc13568.eedblog.com/31995928/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing